LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of June 9, 2026, LLY stock price declined to $1,144.68 with 3,522,214 million shares trading.

LLY has a beta of 0.32, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.01 to the broad based SPY ETF.

LLY has a market cap of $1.02 trillion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $20 billion in Revenue and $8.55 earnings per share. This beat revenue expectation by $2 billion and exceeded earnings estimates by $1.70.

In the last 3 years, LLY traded as high as $1,182.73 and as low as $434.34.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.

LLY has outperformed the market in the last year with a price return of +49.5% while the SPY ETF gained +24.3%. LLY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.8% and +7.5%, respectively, while the SPY returned +9.9% and -1.2%, respectively.

LLY support price is $1,124.05 and resistance is $1,174.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.